Xiuning Le: Firmonertinib for EGFR PACC mutations
Xiuning Le shared a post on X by Hidehito Horinouchi adding:
“Firmonertinib 240mg for EGFR PACC mutations. ORR 63.6% DCR 100%. CNS activities”
Quoting Hidehito Horinouchi’s post below:
“WCLC24 Presidential 2
FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations.”
Read Further.
Source: Xiuning Le/X and Hidehito Horinouchi/X
Xiuning Le, MD, serves as the Deputy Section Chief of Thoracic Medical Oncology at MD Anderson Cancer Center, where she oversees clinical research, including strategic planning and the operation of clinical trials within the department. She is also an Associate Professor and a leading translational researcher, specializing in resistance mechanisms, cancer genetics and genomics, biomarkers, and radiomics.
Hidehito Horinouchi is the Assistant Chief of the National Cancer Center Hospital. He also serves as the Secretary General of the Lung Cancer Study Group, Japan Clinical Oncology Group, and the Deputy Chief of the Center for Education and Professional Career Development at the National Cancer Center Hospital. He specializes in multimodal treatment strategies, including medical, surgical, and radiation oncology, for patients with thoracic malignancies.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023